Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

774.11
-19.6300-2.47%
Pre-market: 782.668.55+1.10%07:27 EDT
Volume:540.84K
Turnover:419.72M
Market Cap:79.70B
PE:19.15
High:788.58
Open:788.53
Low:769.57
Close:793.74
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.99
T/O Rate:0.55%
Dividend:3.64
Dividend Rate:0.47%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.51
PE(LYR):18.66

Loading ...

Regeneron Pharmaceuticals, - Pasatru Under Review by European Medicines Agency; Global Submissions Planned

THOMSON REUTERS
·
Aug 20

Regeneron Pharmaceuticals, - FDA Approves Pasatru (Garetosmab-Grts) for Adults with Fibrodysplasia Ossificans Progressiva

THOMSON REUTERS
·
Aug 20

Movement Alert|Regeneron Pharmaceuticals Rises 3.44% in Regular Trading, Investment Bank Sharply Raises Target Price Amid Biotech Sector Rally

Market Focus
·
Aug 19

What This Top Biotech Fund is Buying Now

Dow Jones
·
Aug 19

Regeneron Pharma Price Target Raised to $824.00/Share from $641.00 by Leerink Partners

Dow Jones
·
Aug 17

EyePoint Tumbles After Experimental Eye Drug Misses Main Goal in Late-Stage Study

Reuters
·
Aug 17

Leerink Partners Adjusts PT on Regeneron Pharmaceuticals to $824 From $641, Maintains Market Perform Rating

MT Newswires Live
·
Aug 17

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

MT Newswires Live
·
Aug 14

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 14

Regeneron Director Huda Y. Zoghbi Disposes of USD 640,000 in Common Shares

Reuters
·
Aug 13

Infinimmune Raises $75 Million Series a Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease

Reuters
·
Aug 11

Infinimmune: $75 Mln Series a Financing Co-Led by Regeneron Ventures and Playground Global

THOMSON REUTERS
·
Aug 11

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 11

Movement Alert|Regeneron Pharmaceuticals Rises 3.01% in Regular Trading, Multiple Catalysts Boost Sentiment

Market Focus
·
Aug 11

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 08

Sanofi, Regeneron Seem Keen to Keep Working Together

Dow Jones
·
Aug 07

Regeneron Posts Transcript of Q2 2026 Earnings Conference Call

Reuters
·
Aug 07

Regeneron Canada Says Libtayo Receives Health Canada Approval for Treatment of a Type of Carcinoma

Reuters
·
Aug 06

Regeneron announces Health Canada approval of new indication for Libtayo

TIPRANKS
·
Aug 06

Regeneron Canada: Libtayo Receives Health Canada Approval for Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma

THOMSON REUTERS
·
Aug 06